Vibostolimab/Pembrolizumab Fails to Reach Statistical Significance in NSCLC

2 years ago 61

The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.

1. Homepage
2. Lung Cancer
3. Vibostolimab/Pembrolizumab Fails to Reach Statistical Significance in NSCLC